~~<i id='991196BAEA'><strike id='991196BAEA'><tt id='991196BAEA'><pre id='991196BAEA'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：entertainment 2025-09-28 07:47:51 Page View：1

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： UnitedHealth’s Optum accused of antitrust violations in California
Next article： At least 13 dead in Texas as scorching temps continue

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

Leukemia patients are helped by Syndax's new type of therapy

AdobeSANDIEGO—OneofthetoughestsubtypesofacuteleukemiainvolvesageneticalterationintheKMT2Agene.Manyca

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

RubyWallauforSTATAbbViewillpay$10billionforthebiotechfirmImmunogen,thecompanysaidThursday,acquiringa